Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$15.04 USD
-0.09 (-0.59%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $15.00 -0.04 (-0.27%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ASMB 15.04 -0.09(-0.59%)
Will ASMB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ASMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASMB
Are Medical Stocks Lagging Entera Bio (ENTX) This Year?
Are Medical Stocks Lagging ASLAN Pharmaceuticals (ASLN) This Year?
ASMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
TEVA Shares Rise on Broad Support for Opioids Settlement
After Plunging 17% in 4 Weeks, Here's Why the Trend Might Reverse for Assembly Biosciences (ASMB)
Assembly Biosciences (ASMB) Upgraded to Strong Buy: Here's Why
Other News for ASMB
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop
H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection
Assembly Biosciences doses first participant in Phase 1b trial of ABI-4334
Assembly Biosciences closes $12.6M in equity financings